

Briony Larance

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9000603/publications.pdf>

Version: 2024-02-01

71
papers

1,770
citations

279798

23
h-index

302126

39
g-index

73
all docs

73
docs citations

73
times ranked

1852
citing authors

#	ARTICLE	IF	CITATIONS
1	Prescription of opioid analgesics and related harms in Australia. Medical Journal of Australia, 2011, 195, 280-284.	1.7	157
2	Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug and Alcohol Review, 2011, 30, 236-245.	2.1	107
3	The Pain and Opioids IN Treatment study. Pain, 2015, 156, 231-242.	4.2	104
4	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Medicine, 2015, 16, 356-366.	1.9	102
5	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. Pain Medicine, 2015, 16, 1745-1758.	1.9	78
6	Injecting risk behaviour and related harm among men who use performance and image enhancing drugs. Drug and Alcohol Review, 2008, 27, 679-686.	2.1	77
7	The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. Pharmacoepidemiology and Drug Safety, 2016, 25, 521-538.	1.9	63
8	Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence, 2011, 118, 265-273.	3.2	62
9	A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction, 2015, 110, 646-655.	3.3	57
10	The availability, diversion and injection of pharmaceutical opioids in South Asia. Drug and Alcohol Review, 2011, 30, 246-254.	2.1	48
11	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction, 2020, 115, 1295-1305.	3.3	46
12	The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug and Alcohol Dependence, 2014, 136, 21-27.	3.2	43
13	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. Pain, 2016, 157, 1489-1498.	4.2	43
14	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. Drug and Alcohol Dependence, 2016, 162, 79-87.	3.2	40
15	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Toxicology, 2014, 15, 17.	2.4	39
16	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoepidemiology and Drug Safety, 2017, 26, 587-591.	1.9	39
17	An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia. European Journal of Clinical Pharmacology, 2016, 72, 469-494.	1.9	37
18	Regulatory and other responses to the pharmaceutical opioid problem. Medical Journal of Australia, 2019, 210, 6.	1.7	36

#	ARTICLE	IF	CITATIONS
19	To what extent do data from pharmaceutical claims underâ€estimate opioid analgesic utilisation in Australia?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 550-555.	1.9	35
20	Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. <i>Drug and Alcohol Review</i> , 2018, 37, S203-S205.	2.1	32
21	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67.	3.2	29
22	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , the, 2018, 5, 155-166.	7.4	28
23	Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. <i>Drug and Alcohol Dependence</i> , 2016, 159, 42-52.	3.2	27
24	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	3.3	22
25	Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. <i>Drug and Alcohol Review</i> , 2011, 30, 613-620.	2.1	21
26	The extramedical use and diversion of opioid substitution medications and other medications in prison settings in <scp>A</scp>ustralia following the introduction of buprenorphineâ€naloxone film. <i>Drug and Alcohol Review</i> , 2016, 35, 76-82.	2.1	21
27	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 51-61.	2.8	20
28	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, nonâ€adherence and diversion of opioids: the <scp>N</scp>ational <scp>O</scp>pioid <scp>M</scp>edications <scp>A</scp>buse <scp>D</scp>eterrence (<scp>NOMAD</scp>) study protocol. <i>Addiction</i> , 2015, 110, 226-237.	3.3	19
29	Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2018, 191, 145-151.	3.2	18
30	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020, 28, 100592.	7.1	16
31	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 83-91.	2.1	15
32	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55.	3.2	14
33	Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. <i>International Journal of Drug Policy</i> , 2015, 26, 1265-1272.	3.3	13
34	Diversion of prescribed opioids by people living with chronic pain: Results from an <scp>A</scp>ustralian community sample. <i>Drug and Alcohol Review</i> , 2014, 33, 27-32.	2.1	11
35	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	3.2	11
36	Postâ€marketing studies of pharmaceutical opioid abuseâ€deterrent formulations: a framework for research design and reporting. <i>Addiction</i> , 2019, 114, 389-399.	3.3	11

#	ARTICLE	IF	CITATIONS
37	Substance Use and Co-occurring Physical Health Problems: File Review of a Residential Drug and Alcohol Treatment Service. <i>Journal of Dual Diagnosis</i> , 2020, 16, 250-259.	1.2	11
38	SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108568.	2.8	11
39	Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. <i>International Journal of Drug Policy</i> , 2022, 99, 103472.	3.3	11
40	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015, 34, 611-622.	2.1	10
41	Geographic Variation in Health Service Use and Perceived Access Barriers for Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy. <i>Pain Medicine</i> , 2016, 17, 2003-2016.	1.9	10
42	Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107697.	3.2	10
43	The POPPY Research Programme protocol: investigating opioid utilisation, costs and patterns of extramedical use in Australia. <i>BMJ Open</i> , 2015, 5, e007030-e007030.	1.9	9
44	Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. <i>Cmaj</i> , 2018, 190, E355-E362.	2.0	9
45	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 758-769.	1.9	9
46	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389.	1.9	9
47	Routine outcome measurement in specialist non-government alcohol and other drug treatment services: Establishing effectiveness indicators for the <scp>NADA</scp>base. <i>Drug and Alcohol Review</i> , 2021, 40, 540-552.	2.1	9
48	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015, 34, 603-610.	2.1	8
49	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020, 21, e79-e88.	1.9	8
50	A population-based study of transdermal fentanyl initiation in Australian clinical practice. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 401-408.	1.9	8
51	Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in Mutual Support Groups Coordinated by SMART Recovery Australia: Protocol for a Pilot Study. <i>JMIR Research Protocols</i> , 2020, 9, e15113.	1.0	8
52	Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in SMART Recovery Mutual Support Groups: Stage 1 Mixed Methods Pilot Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e25217.	4.3	8
53	Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Review</i> , 2020, 39, 128-134.	2.1	7
54	Facilitators and barriers to integrating physical health care during treatment for substance use: A socio-ecological analysis. <i>Drug and Alcohol Review</i> , 2021, 40, 607-616.	2.1	7

#	ARTICLE	IF	CITATIONS
55	Characteristics and circumstances of death related to buprenorphine toxicity in Australia. Drug and Alcohol Dependence, 2021, 218, 108360.	3.2	7
56	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. Drug and Alcohol Review, 2022, 41, 841-850.	2.1	7
57	Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. Drug and Alcohol Review, 2015, 34, 623-629.	2.1	6
58	Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims. Pain Medicine, 2018, 19, 1170-1183.	1.9	6
59	Circumstances of death of opioid users being treated with naltrexone. Addiction, 2019, 114, 2000-2007.	3.3	6
60	Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study. Pharmacoepidemiology and Drug Safety, 2019, 28, 97-105.	1.9	6
61	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. Pharmacoepidemiology and Drug Safety, 2015, 24, 1321-1333.	1.9	4
62	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. JAMA Network Open, 2021, 4, e213059.	5.9	4
63	The use of Australian SMART Recovery groups by people who use methamphetamine: Analysis of routinely-collected nationwide data. Drug and Alcohol Dependence, 2021, 225, 108814.	3.2	4
64	Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations. Lancet Psychiatry, 2015, 2, 957-959.	7.4	3
65	Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol. BMJ Open, 2018, 8, e020006.	1.9	3
66	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. Addiction, 2021, 116, 1482-1494.	3.3	3
67	Systematic review of guidelines for managing physical health during treatment for substance use disorders: Implications for the alcohol and other drug workforce. Drug and Alcohol Review, 2022, 41, 1367-1390.	2.1	3
68	Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations. Addiction, 2019, 114, 404-405.	3.3	2
69	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain. International Journal of Drug Policy, 2022, 105, 103708.	3.3	2
70	Preliminary psychometric evaluation of the patient reported experience measure for addiction treatment (PREMAT). Addictive Behaviors, 2021, 123, 107048.	3.0	1
71	Trends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007-2015. Drug and Alcohol Review, 2019, 38, 159-168.	2.1	0